Inogen, Inc.

What they do

Inogen develops, manufactures, and markets portable oxygen concentrators (POCs) that concentrate ambient air to deliver supplemental long-term oxygen therapy, sold under the Inogen One and Inogen Rove brands. It also sells the Simeox mucus management device for airway clearance, acquired with Physio-Assist in 2023. Under a 2025 collaboration with Jiangsu Yuyue Medical Equipment & Supply (Yuwell), it distributes the Inogen Voxi 5 stationary oxygen concentrator and Aurora CPAP masks in the U.S., and Yuwell distributes certain Inogen POCs in select Asia-Pacific countries. Revenue comes from product sales and rentals, and the company also offers extended payment terms to some customers.

Revenue drivers

• Portable oxygen concentrators (POCs) — Core Inogen One and Rove POC systems sold and rented for long-term oxygen therapy; the 10-Q and 8-K cite higher international demand for POCs as the main driver of second-quarter growth.
• Yuwell-distributed products — U.S. distribution of the Voxi 5 stationary oxygen concentrator and Aurora CPAP masks under the January 2025 collaboration, which has broadened the U.S. product portfolio; Inogen received $27.2 million from Yuwell in 2025.
• Simeox airway clearance — Technology-enabled mucus management device from the Physio-Assist acquisition, aimed at bronchiectasis, cystic fibrosis, and COPD patients; a China H SCOPE study completed enrollment in the second quarter of 2026.
• International revenue — Second-quarter 2026 international revenue was $41.3 million, up 14.8% year-over-year, while U.S. sales and rentals remained below the prior-year period.

Recent performance

Second-quarter 2026 revenue was $95.1 million, up 3.0% from $92.3 million a year earlier, with international revenue of $41.3 million up 14.8%. GAAP net loss was $3.9 million versus a $4.2 million loss in the prior-year period, and adjusted EBITDA was positive $2.4 million versus positive $2.1 million. Total gross margin was 45.5% versus 44.8%, and adjusted gross margin improved 65 basis points to 45.6%. Operating cash flow was positive $2.9 million in the quarter; cash, cash equivalents, marketable securities, and restricted cash were $106.8 million at June 30, 2026, with no debt outstanding.

Strategy

Inogen is diversifying beyond POCs into a broader respiratory portfolio through the Yuwell collaboration, which added U.S. distribution of the Voxi 5 stationary concentrator and Aurora CPAP masks and is intended to accelerate entry into the Chinese market. The company is pursuing international expansion, including launching the Rove 6 POC in Canada and completing enrollment in the Simeox H SCOPE study in China. It repurchased 1,145,150 shares for $7.5 million in the first half of 2026 under a program announced in the first quarter, and added Andy Reding as Chief Operating Officer. Management states it is prioritizing investments to balance growth, profitability, and innovation, and raised full-year adjusted EBITDA guidance.

Risks

• Customer concentration — The 10-K states Inogen depends on a limited number of customers for a significant portion of sales revenue both domestically and internationally.
• Reimbursement pressure — A significant portion of revenue depends on a complex and lengthy reimbursement process, and changes in Medicare, Medicaid, and private payor rates or payment methodologies could affect results.
• Supply chain dependence — The company relies on a single source or a limited group of manufacturers or suppliers for its products.
• U.S. demand softness — U.S. sales and rentals remained below the prior-year period in the second quarter of 2026, even as international revenue grew.

Outlook

Management raised full-year 2026 adjusted EBITDA guidance to approximately $4.0 million, a 48.1% increase from the $2.7 million reported in 2025, and updated full-year revenue guidance to $355 million to $361 million, roughly 3% growth at the midpoint. Statistical analysis results from the Simeox H SCOPE Study in China are expected in the second half of 2026. The company states it has no debt outstanding and believes current cash, cash equivalents, and marketable securities will meet projected operating and investing requirements for at least the next 12 months.